Press Releases

Dr. Treiber brings more than 20 years experience in the clinical and medical research industries with a strong background in delivering contract research services to Pharmaceutical and Biotechnology clients. He will be responsible for all aspects of clinical monitoring and project management at inVentiv Clinical, including executive project oversight and client interaction for full service clinical trials managed by the company. Dr. Treiber will be located in inVentiv Clinical's Chicago office.

Prior to joining inVentiv, Dr. Treiber held positions of increasing responsibility at several clinical contract research organizations (CRO), including Quintiles, ICON and Premier Research. Most recently, he was Vice President of Clinical Research for PharmaNet, with overall responsibility for the Neuroscience, Cardiovascular/General Medicine, Ophthalmology and Dermatology therapeutic divisions. Dr. Treiber received his PhD in Biology from the University of California at Santa Cruz and his MBA from Ellis College of the New York Institute of Technology.

“We are pleased to have Dr. Treiber join the inVentiv Clinical senior management team," said Mike Hlinak, President and CEO of inVentiv Clinical. "Dr. Treiber brings invaluable experience from his long and progressive tenure in the CRO industry and will be integral to inVentiv’s commitment to delivering high quality clinical operations oversight to our growing list of full service clinical trial clients." This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.